Clinical Trials

26 enrolled

Lymphoma

NCT07221500 2026-04-14

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

LymphoidOther hematologic neoplasm

100 enrolled

Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02465060 2026-04-13

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

6,452 enrolled 2 FDA

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04439201 2026-04-13

Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

LymphoidOther hematologic neoplasm

40 enrolled 9 charts

Lymphoma, Hematologic Neoplasms

NCT04439292 2026-04-13

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

35 enrolled

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439318 2026-04-13

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

50 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439331 2026-04-13

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT04439357 2026-04-13

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

4 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT05490771 2026-04-13

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

Lymphoma, Multiple Myeloma

NCT06303167 2026-04-13

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

19 enrolled 10 charts

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT06308822 2026-04-13

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

35 enrolled 9 charts

Lymphoma, Multiple Myeloma

NCT06390839 2026-04-13

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

43 enrolled 10 charts

Lymphoma

NCT06400225 2026-04-13

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

35 enrolled

Lymphoma, Multiple Myeloma

NCT06400238 2026-04-13

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

Lymphoma, Multiple Myeloma

NCT06400251 2026-04-13

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

Lymphoma, Multiple Myeloma

NCT03258567 2026-04-08

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

40 enrolled

Lymphoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

NCT06385483 2026-04-07

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

19 enrolled 10 charts

Lymphoma, Multiple Myeloma

NCT06390826 2026-04-07

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

10 enrolled 10 charts

Lymphoma, Multiple Myeloma

NCT07030699 2026-04-07

ECLAT

Phase 2 Withdrawn

Lymphoma

NCT06692452 2026-04-01

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Phase 2 Withdrawn

Phase 2 Not yet recruiting

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Peripheral, Enteropathy-Associated T-Cell Lymphoma

NCT07502872 2026-03-31

TPG

30 enrolled

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00428142 2026-03-27

Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

Phase 2 Completed

95 enrolled

Lymphoma, Lymphoma, Follicular

NCT02436707 2026-03-27

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

129 enrolled

Lymphoma

NCT03793140 2026-03-27

A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

LymphoidOther hematologic neoplasm

24 enrolled

Burkitt Lymphoma, Leukemia, Lymphoma

NCT06915246 2026-03-27

A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma

49 enrolled

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin

NCT07015242 2026-03-24

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

65 enrolled

Lymphoma

NCT06360575 2026-03-20

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

20 enrolled 10 charts

Lymphoma, Multiple Myeloma

NCT01315132 2026-03-19

A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies

Phase 2 Completed

47 enrolled 8 charts

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT06357975 2026-03-19

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

44 enrolled 10 charts

Lymphoma, Multiple Myeloma

NCT02952508 2026-03-18

CLOVER-WaM

120 enrolled

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

NCT04904588 2026-03-18

ACCESS

LymphoidMyeloidOther hematologic neoplasmOther neoplasm

300 enrolled

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Leukemia, Myeloid, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Myelodysplastic Syndromes, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06859424 2026-03-17

ACCELERATE